Oral Session 2-7C ATL: Treatment

[OS2-7C-1] Monitoring of immune response following mogamulizumab-containing chemotherapy in ATL -interim report-

Ilseung Choi¹, Shigeru Kusumoto², Nobuaki Nakano³, Asahi Ito², Kentaro Yonekura³, Yoshitaka Imaizumi⁴, Makoto Yoshimitsu⁵, Kisato Nosaka⁶, Eiichi Otsuka⁷, Michihiro Hidaka⁸, Tatsuro Jo⁹, Hidenori Sasaki¹⁰, Yukiyoshi Moriuchi¹¹, Masao Ogata¹², Yoko Suehiro¹, Ryuzo Ueda¹³, Atae Utsunomiya³, Takashi Ishida² (1.Department of Hematology NHO Kyushu Cancer Center Fukuoka Japan, 2.Department of Hematology and Oncology, Nagoya City University, 3.Department of Hematology, Imamura General Hospital, 4.Department of Hematology, Atomic Disease Institute, Nagasaki University, 5.Department of Hematology and Immunology, Kagoshima University, 6.Department of Hematology, Kumamoto University, 7.Department of Hematology, Oita Prefectural Hospital, 8.Department of Hematology, NHO Kumamoto Medical Center, 9.Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, 10.Division of Medical Oncology, Hematology, and Infectious Diseases, Fukuoka University, 11.Department of Hematology, Sasebo City General Hospital, 12.Department of Hematology, Oita University, 13.Department of Tumor Immunology, Aichi Medical University School of Medicine)